@BroadInstitute a shift from Permanently editing DNA to Temporarily revising RNA – An approach with promise for addressing the risk of developing Alzheimer’s by deactivating APOE4 – RESCUE: RNA Editing for Specific C to U Exchange, the platform builds on REPAIR: RNA Editing for Programmable A to I
Reporter: Aviva Lev-Ari, PhD, RN
UPDATED on 8/30/2021
- Brief Communication
- Published:
Compact RNA editors with small Cas13 proteins
Nature Biotechnology (2021)
Abstract
CRISPR–Cas13 systems have been developed for precise RNA editing, and can potentially be used therapeutically when temporary changes are desirable or when DNA editing is challenging. We have identified and characterized an ultrasmall family of Cas13b proteins—Cas13bt—that can mediate mammalian transcript knockdown. We have engineered compact variants of REPAIR and RESCUE RNA editors by functionalizing Cas13bt with adenosine and cytosine deaminase domains, and demonstrated packaging of the editors within a single adeno-associated virus.
SOURCE
Kannan, S., Altae-Tran, H., Jin, X. et al. Compact RNA editors with small Cas13 proteins. Nat Biotechnol (2021). https://doi.org/10.1038/s41587-021-01030-2
https://www.nature.com/articles/s41587-021-01030-2
2.1.3.14 @BroadInstitute a shift from Permanently editing DNA to Temporarily revising RNA – An approach with promise for addressing the risk of developing Alzheimer’s by deactivating APOE4 – RESCUE: RNA Editing for Specific C to U Exchange, the platform builds on REPAIR: RNA Editing for Programmable A to I, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair
- The RNA editors converted “the nucleotide base adenine to inosine, or letters A to I. Zhang and colleagues took the REPAIR fusion and evolved it in the lab until it could change cytosine to uridine, or C to U.”
- Using Cas13, Zhang’s team was able to take the APOE4 gene — believed to carry the added risk of spurring Alzheimer’s — and changed it to a benign APOE2.
RNA-guided DNA insertion with CRISPR-associated transposases
Other related articles on CRISPR derived Gene Editing for Gene Therapy published in this Open Access on Online Scientific Journal include the following:
Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Forthcoming 12/2019, Volume Two
by
Prof. Marcus W. Feldman, PhD, Editor, Stanford University
Prof. Stephen J. Williams, PhD, Editor, Temple University
and Aviva Lev-Ari, PhD, RN, Editor, LPBI Group
Part 2: CRISPR for Gene Editing and DNA Repair
2.1 The Science – 77 articles
2.2 Technologies and Methodologies – 27 articles
2.3 Clinical Aspects – 9 articles
2.4 Business and Legal – 18 articles
Series B: Frontiers in Genomics Research
- VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015
Leave a Reply